SGC-CBP30

Research use only, not for human use.

SGC-CBP30 is an effective CREBBP/EP300 inhibitor (IC50: 21/38 nM).

SGC-CBP30 is a potent and selective inhibitor of CREBBP (CBP) and EP300; which are general transcriptional co-activators. CREBBP has also been associated with Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig?’s disease, a neurodegenerative disease with progressive degeneration of motor neurons in the brain and spinal cord, Alzheimer's disease and poly glutamine repeat diseases such as Spinal and Bulbar Muscular Atrophy and Huntington?’s disease.

——

Animal Model:Sprague-Dawley (SD) rats (aged 3-4 weeks) injected with NSC-125066 Dosage:25 mg/kg Administration:Oral administration; daily; for 14 days Result:Slightly alleviated alveolar bronchial fibrosis induced by NSC-125066.

SGC-CBP30 | SGC-CBP 30 | SGC-CBP-30

Others

Other Targets

CREBBP| EP300

Cancer

——

1613695-14-9

509.04

C28H33CIN4O3

>98% (HPLC)

DMSO : ≥ 31 mg/mL; 60.90 mM

Cc1noc(C)c1c1cc2nc(CCc3ccc(OC)c(Cl)c3)n(C[C@H](C)N3CCOCC3)c2cc1

(S)-4-(1-(2-(3-chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-1-yl)propan-2-yl)morpholine

(-20℃)

With Ice Pack

≥ 2 years